FDA Grants EUA To Baricitinib-Remdesivir Combo For COVID-19

By Beth Wang / November 19, 2020 at 6:14 PM
FDA on Thursday (Nov. 19) granted emergency authorization to Eli Lilly’s anti-inflammatory drug baricitinib to be used in combination with Gilead’s antiviral remdesivir for treatment of COVID-19 in hospitalized adult and pediatric patients who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. The EUA for baricitinib is the first emergency authorization of a drug that acts on the inflammation pathway, Patrizia Cavazzoni, acting director of FDA’s drug center, said in a press statement. “Despite advances in the management of...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.